{"id":17891,"date":"2025-09-09T10:47:41","date_gmt":"2025-09-09T16:47:41","guid":{"rendered":"https:\/\/immunotherapymx.com\/?page_id=17891"},"modified":"2026-02-12T15:28:04","modified_gmt":"2026-02-12T21:28:04","slug":"ciencia","status":"publish","type":"page","link":"https:\/\/immunotherapymx.com\/es\/ciencia\/","title":{"rendered":"Ciencia"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Evidence-guided regenerative biotechnology<\/h1>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Personalized protocols designed with explicit safety criteria<\/strong> and objective follow-up<\/strong>. Each preparation is released only after documented quality controls<\/strong> (viability, sterility, endotoxins) and is grounded in three levels of evidence: in vitro studies, preclinical models, and early clinical signals<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Our Scientific Approach<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We work with clinical biotechnology and a framework of three levels of evidence<\/strong>: in vitro studies, in vivo validation, and early clinical signals<\/strong>. On that basis, we design personalized protocols<\/strong> under explicit safety, eligibility, and objective follow-up<\/strong> criteria. We do not transfer findings outside their context or communicate benefits without support. Operational details are protected by clinical confidentiality<\/strong>, without affecting the traceability<\/strong> or transparency<\/strong> of results.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

Biomaterials and Tissue Microenvironments<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We develop and validate bioactive scaffolds<\/strong> and functionalized surfaces<\/strong> (e.g., PCL\/PLGA, chitosan, 3D textiles) that replicate features of the extracellular matrix<\/strong> to promote adhesion, protection, and cell signaling<\/strong>. These \u201cmicrohabitats\u201d aim to guide repair<\/strong> and improve integration with existing tissue<\/strong>, with measurable effects on osteogenic markers and cell\u2013matrix interaction<\/strong>. Any transition to clinical use requires biocompatibility and reproducible performance<\/strong> in preclinical models, with documentation and batch-level traceability.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

Immunometabolism and High-Purity Phytoactives<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We evaluate standardized bioactive extracts<\/strong> (antioxidant\/anti-inflammatory profile) and their impact on oxidative stress<\/strong>, telomeric dynamics<\/strong>, and metabolic markers<\/strong>. The goal is to modulate systemic inflammation<\/strong> and support patient homeostasis<\/strong> within a comprehensive approach<\/strong>. We only consider compounds with analytical purity and traceability<\/strong>; potential uses are integrated when supported by data<\/strong>, communicating scope and limits<\/strong> to avoid extrapolations.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

Biosensors, Bioimpedance, and Precision Medicine<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We apply electrical bioimpedance<\/strong>, QCM-D<\/strong>, and gene-expression panels<\/strong> to quantify biological processes (inflammation, tissue integrity, microbiota dynamics<\/strong>) and monitor response<\/strong> throughout the therapeutic plan. Together with clinical biomarkers<\/strong> and validated scales<\/strong>, these measures allow us to adjust doses and intervals<\/strong> using objective criteria. We prioritize repeatable measurements<\/strong>, data quality<\/strong> control, and traceability<\/strong>. These are support tools: they do not replace<\/strong> clinical judgment.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

Cell Biology and Immune Modulation<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Regeneration depends on both cells<\/strong> and the immune milieu<\/strong>. We study how macrophages<\/strong> and other immune cells influence repair: early pro-inflammatory phases can recruit progenitors<\/strong> and activate osteogenic<\/strong> pathways (e.g., BMP-2<\/strong>, RUNX2<\/strong>), while resolution phases promote maturation and remodeling<\/strong>. We explore their modulation<\/strong> via biomolecules and material cues<\/strong> (including nano\/hybrid materials), always assessing biocompatibility, safety, and functionality<\/strong> in in vitro and in vivo systems before considering clinical applications.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

Immunogenetics and Compatibility<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We analyze histocompatibility markers (HLA)<\/strong> and other immunogenetic<\/strong> determinants to support decisions on compatibility<\/strong>, donor selection<\/strong>, and eligibility criteria<\/strong> where applicable. This profile helps anticipate immune interactions<\/strong> and refine strategy in scenarios where the immune system response<\/strong> conditions the outcome. We also consider factors such as immunosenescence<\/strong> and autoimmunity<\/strong> to personalize<\/strong> the protocol. These analyses guide decisions but do not, by themselves, determine<\/strong> the therapeutic indication.<\/p><\/div><\/div><\/div><\/div><\/div><\/div><\/article>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Our Academic Collaborations\n<\/h1>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We take part in joint projects with universities and research centers<\/strong> that allow us to test methodologies in external settings, ensure that results are reproducible<\/strong>, and maintain an ongoing dialogue with the scientific community. These partnerships provide transparency and independent review<\/strong>, and help ensure that every clinical advance is developed under the same standard of rigor that guides international academic research.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Immunotherapy\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

How We Work \u00b7 Quality and Safety<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Priority: safety<\/strong> and objective measurement<\/strong>. Every case begins with a comprehensive clinical assessment<\/strong> and defined eligibility criteria<\/strong>. We only release<\/strong> a preparation if it meets viability, sterility, and endotoxin<\/strong> requirements. Follow-up relies on validated scales<\/strong> and biomarkers<\/strong>; we adjust the strategy based on the data. No outcome guarantees<\/strong>, with batch-level traceability<\/strong> and clinical confidentiality<\/strong> at all times.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\r\n\r\n
\r\n
    \r\n
  1. \r\n 1<\/span>\r\n Collection \/ Procurement<\/span>\r\n Documentation and traceability<\/span>\r\n <\/li>\r\n
  2. \r\n 2<\/span>\r\n Fresh Processing<\/span>\r\n Controlled conditions (same day)<\/span>\r\n <\/li>\r\n
  3. \r\n 3<\/span>\r\n Quality Control<\/span>\r\n Viability \u00b7 Sterility \u00b7 Endotoxins<\/span>\r\n <\/li>\r\n
  4. \r\n 4<\/span>\r\n Administration<\/span>\r\n IV \u00b7 IM \u00b7 Intra-articular<\/span>\r\n <\/li>\r\n <\/ol>\r\n<\/div>\r\n\r\n